8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 16, 2026·SEC
Material company update
Mar 6, 2026·SEC
Amphastar Pharmaceuticals, Inc.(AMPH)Earnings, Financials & Key Ratios
AMPH•NASDAQ
9.3× P/E·Price updated Jun 19, 2026
AboutAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Show more
- Revenue$720M-1.7%
- EBITDA$149M-43.2%
- Net Income$98M-38.5%
- EPS (Diluted)2.03-33.7%
- Gross Margin49.46%-3.2%
- EBITDA Margin20.71%-42.3%
- Operating Margin19.5%-30.5%
- Net Margin13.63%-37.5%
- ROE12.9%-44.5%
AMPH Key Insights
Amphastar Pharmaceuticals, Inc. (AMPH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 133.8%
- ✓FCF machine: 16.8% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 15.5%
- ✓Good 3Y average ROE of 19.9%
- ✓Share count reduced 7.4% through buybacks
✗Weaknesses
- ✗Weak momentum: RS Rating 20 (bottom 20%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AMPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AMPH Price & Volume
Amphastar Pharmaceuticals, Inc. (AMPH) stock price & volume — 10-year historical chart
Loading chart...
AMPH Growth Metrics
Amphastar Pharmaceuticals, Inc. (AMPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.09%
5 Years15.53%
3 Years12.99%
TTM-1.06%
Profit CAGR
10 Years-
5 Years133.84%
3 Years2.39%
TTM-44.06%
EPS CAGR
10 Years-
5 Years134.54%
3 Years5.27%
TTM-39.86%
Return on Capital
10 Years8.02%
5 Years15.19%
3 Years15.13%
Last Year9.77%
AMPH Recent Earnings
Amphastar Pharmaceuticals, Inc. (AMPH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.42-40.0%
$0.70
Rev
$171M-1.3%
$173M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.73-19.2%
$0.90
Rev
$183M-3.0%
$189M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.93+20.8%
$0.77
Rev
$192M+0.7%
$190M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.85+19.7%
$0.71
Rev
$174M-1.5%
$177M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.42vs $0.70-40.0% | $171Mvs $173M-1.3% |
| Q1 2026 | Feb 26, 2026 | $0.73vs $0.90-19.2% | $183Mvs $189M-3.0% |
| Q4 2025 | Nov 6, 2025 | $0.93vs $0.77+20.8% | $192Mvs $190M+0.7% |
| Q3 2025 | Aug 7, 2025 | $0.85vs $0.71+19.7% | $174Mvs $177M-1.5% |
Based on last 12 quarters of dataView full earnings history →
AMPH Peer Comparison
Amphastar Pharmaceuticals, Inc. (AMPH) competitors in Complex generics and injectables — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 PCRX | 878.35M | 22.33 | 139.56 | 3.63% | 1.27% | 1.31% | 0.66 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 | |||
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 | |
 AKBA | 287.04M | 1.07 | -51.44 | 47.46% | -8.83% | -62.72% | 6.63 | |
 MNKD | 1.22B | 3.94 | 197 | 22.23% | -6.63% | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 |
Compare AMPH vs Peers
Amphastar Pharmaceuticals, Inc. (AMPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AMPH Income Statement
Amphastar Pharmaceuticals, Inc. (AMPH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 240.18M | 294.67M | 322.36M | 349.85M | 437.77M | 498.99M | 644.39M | 731.97M | 719.89M | 720.53M |
Revenue Growth % | -5.87% | 22.69% | 9.4% | 8.53% | 25.13% | 13.98% | 29.14% | 13.59% | -1.65% | -1.06% |
Cost of Goods Sold | 149.38M | 187.68M | 190.43M | 206.51M | 238.03M | 250.13M | 293.27M | 358.11M | 363.83M | 379.4M |
COGS % of Revenue | 62.2% | 63.69% | 59.08% | 59.03% | 54.37% | 50.13% | 45.51% | 48.92% | 50.54% | - |
Gross Profit | 90.8M▲ 0% | 106.98M▲ 17.8% | 131.92M▲ 23.3% | 143.34M▲ 8.7% | 199.74M▲ 39.3% | 248.86M▲ 24.6% | 351.12M▲ 41.1% | 373.86M▲ 6.5% | 356.06M▼ 4.8% | 341.13M▲ 0% |
Gross Margin % | 37.8% | 36.31% | 40.92% | 40.97% | 45.63% | 49.87% | 54.49% | 51.08% | 49.46% | 47.34% |
Gross Profit Growth % | -12.86% | 17.83% | 23.31% | 8.65% | 39.35% | 24.59% | 41.09% | 6.47% | -4.76% | - |
Operating Expenses | 94.33M | 115.61M | 131.96M | 132.39M | 129.85M | 141.36M | 154.13M | 168.44M | 215.65M | 224.39M |
OpEx % of Revenue | 39.28% | 39.23% | 40.94% | 37.84% | 29.66% | 28.33% | 23.92% | 23.01% | 29.96% | - |
Selling, General & Admin | 50.92M | 58.04M | 63.11M | 65.16M | 68.92M | 66.59M | 80.39M | 94.52M | 129.81M | 131.9M |
SG&A % of Revenue | 21.2% | 19.7% | 19.58% | 18.62% | 15.74% | 13.35% | 12.48% | 12.91% | 18.03% | - |
Research & Development | 43.41M | 57.56M | 68.85M | 67.23M | 60.93M | 74.77M | 73.74M | 73.91M | 85.84M | 92.48M |
R&D % of Revenue | 18.08% | 19.54% | 21.36% | 19.22% | 13.92% | 14.98% | 11.44% | 10.1% | 11.92% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -895K▲ 0% | -8.62M▼ 863.5% | -39K▲ 99.5% | 10.95M▲ 28187.2% | 69.89M▲ 538.0% | 107.5M▲ 53.8% | 196.99M▲ 83.2% | 205.42M▲ 4.3% | 140.4M▼ 31.7% | 116.74M▲ 0% |
Operating Margin % | -0.37% | -2.93% | -0.01% | 3.13% | 15.96% | 21.54% | 30.57% | 28.06% | 19.5% | 16.2% |
Operating Income Growth % | -105.7% | -863.46% | 99.55% | 28187.18% | 538% | 53.82% | 83.25% | 4.28% | -31.65% | - |
EBITDA | 14.91M | 7.89M | 21.08M | 36.13M | 96.42M | 135.77M | 238.76M | 262.62M | 149.1M | 150.05M |
EBITDA Margin % | 6.21% | 2.68% | 6.54% | 10.33% | 22.03% | 27.21% | 37.05% | 35.88% | 20.71% | 20.82% |
EBITDA Growth % | -50.7% | -47.08% | 167.1% | 71.4% | 166.84% | 40.81% | 75.86% | 9.99% | -43.22% | -40.73% |
D&A (Non-Cash Add-back) | 15.81M | 16.52M | 21.12M | 25.18M | 26.53M | 28.27M | 41.78M | 57.2M | 0 | 30.37M |
EBIT | 2.08M | -9.68M | 60.35M | 5.01M | 85.02M | 117.89M | 198.52M | 220.11M | 149.1M | 125.59M |
Net Interest Income | -401K | 213K | 878K | 268K | -284K | -525K | -21.7M | -19.73M | -16.8M | -16.76M |
Interest Income | 425K | 456K | 997K | 642K | 601K | 1.32M | 5.46M | 10.61M | 8.68M | 8.99M |
Interest Expense | 826K | 243K | 119K | 374K | 885K | 1.85M | 27.16M | 30.34M | 25.48M | 25.75M |
Other Income/Expense | 2.52M | -1.3M | 60.27M | -6.32M | 14.04M | 7.37M | -27.61M | -16.23M | -16.78M | -13.93M |
Pretax Income | 1.62M▲ 0% | -9.93M▼ 711.6% | 60.23M▲ 706.8% | 4.64M▼ 92.3% | 83.93M▲ 1710.0% | 114.86M▲ 36.9% | 169.38M▲ 47.5% | 189.19M▲ 11.7% | 123.62M▼ 34.7% | 102.81M▲ 0% |
Pretax Margin % | 0.68% | -3.37% | 18.68% | 1.33% | 19.17% | 23.02% | 26.28% | 25.85% | 17.17% | 14.27% |
Income Tax | -2.88M | -3.27M | 13.72M | 3.54M | 20.63M | 23.48M | 31.83M | 29.67M | 25.53M | 23.59M |
Effective Tax Rate % | -177.76% | 32.9% | 22.79% | 76.34% | 24.58% | 20.44% | 18.79% | 15.68% | 20.65% | 22.94% |
Net Income | 4.51M▲ 0% | -5.74M▼ 227.3% | 48.94M▲ 952.9% | 1.4M▼ 97.1% | 62.12M▲ 4327.4% | 91.39M▲ 47.1% | 137.54M▲ 50.5% | 159.52M▲ 16.0% | 98.09M▼ 38.5% | 79.23M▲ 0% |
Net Margin % | 1.88% | -1.95% | 15.18% | 0.4% | 14.19% | 18.31% | 21.34% | 21.79% | 13.63% | 11% |
Net Income Growth % | -57.2% | -227.28% | 952.89% | -97.13% | 4327.37% | 47.12% | 50.51% | 15.98% | -38.51% | -44.06% |
Net Income (Continuing) | 3.65M | -6.66M | 46.51M | 1.1M | 63.3M | 91.39M | 137.54M | 159.52M | 98.09M | 79.23M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 31.92M | 46.16M | 46.42M | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.09▲ 0% | -0.12▼ 233.3% | 0.98▲ 916.7% | 0.03▼ 97.1% | 1.25▲ 4270.6% | 1.74▲ 39.2% | 2.60▲ 49.4% | 3.06▲ 17.7% | 2.03▼ 33.7% | 1.71▲ 0% |
EPS Growth % | -59.09% | -233.33% | 916.67% | -97.08% | 4270.63% | 39.2% | 49.43% | 17.69% | -33.66% | -39.86% |
EPS (Basic) | 0.10 | -0.12 | 1.04 | 0.03 | 1.30 | 1.88 | 2.85 | 3.29 | 2.10 | - |
Diluted Shares Outstanding | 48.37M | 46.4M | 49.91M | 49.12M | 49.78M | 52.43M | 53M | 52.06M | 48.22M | 46.46M |
Basic Shares Outstanding | 46.11M | 46.4M | 46.98M | 47.04M | 47.78M | 48.55M | 48.27M | 48.43M | 46.74M | 45.32M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AMPH Balance Sheet
Amphastar Pharmaceuticals, Inc. (AMPH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 187.78M | 220.34M | 255.24M | 279.68M | 318.12M | 378.32M | 489.6M | 534.07M | 636.02M | 633.68M |
Cash & Short-Term Investments | 68.23M | 89.17M | 89.52M | 105.62M | 136.67M | 175.76M | 256.81M | 221.65M | 282.81M | 294.39M |
Cash Only | 65.59M | 86.34M | 75.55M | 92.64M | 126.35M | 156.1M | 144.3M | 151.61M | 170.18M | 171.17M |
Short-Term Investments | 2.63M | 2.83M | 13.96M | 12.98M | 10.32M | 19.66M | 112.51M | 70.04M | 112.64M | 123.21M |
Accounts Receivable | 36M | 52.16M | 45.38M | 66M | 78.8M | 88.8M | 115.47M | 138.04M | 143.56M | 147.85M |
Days Sales Outstanding | 54.7 | 64.61 | 51.38 | 68.86 | 65.7 | 64.96 | 65.4 | 68.83 | 72.79 | 72.54 |
Inventory | 63.61M | 69.32M | 110.5M | 96.83M | 92.81M | 103.58M | 105.83M | 153.74M | 176.89M | 170.19M |
Days Inventory Outstanding | 155.42 | 134.82 | 211.79 | 171.15 | 142.31 | 151.16 | 131.72 | 156.7 | 177.46 | 174.31 |
Other Current Assets | 10.19M | 4.2M | 9.85M | 4.45M | 2.56M | 2.61M | 11.49M | 20.65M | 32.75M | 21.25M |
Total Non-Current Assets | 266.89M | 293.22M | 331.73M | 351.55M | 353.41M | 363.67M | 1.02B | 1.04B | 993.28M | 1.01B |
Property, Plant & Equipment | 185.34M | 210.42M | 253.55M | 280.71M | 271.49M | 264.57M | 315.64M | 344.63M | 353.72M | 378.91M |
Fixed Asset Turnover | 1.30x | 1.40x | 1.27x | 1.25x | 1.61x | 1.89x | 2.04x | 2.12x | 2.04x | 2.00x |
Goodwill | 4.46M | 3.95M | 3.63M | 3.94M | 3.31M | 3.13M | 3.22M | 3.05M | 3.4M | 3.33M |
Intangible Assets | 40.68M | 38.32M | 37.52M | 36.67M | 35.56M | 34.17M | 610.08M | 587.61M | 562.56M | 556.29M |
Long-Term Investments | 0 | 0 | 0 | 0 | 3.98M | 2.41M | 15.21M | 11M | 0 | 2.05M |
Other Non-Current Assets | 8.66M | 9.92M | 11.16M | 5.25M | 16.66M | 20.86M | 25.91M | 25.99M | 31.14M | 33.48M |
Total Assets | 454.67M▲ 0% | 513.56M▲ 13.0% | 586.97M▲ 14.3% | 631.24M▲ 7.5% | 671.53M▲ 6.4% | 741.99M▲ 10.5% | 1.51B▲ 103.9% | 1.58B▲ 4.3% | 1.63B▲ 3.3% | 1.65B▲ 0% |
Asset Turnover | 0.53x | 0.57x | 0.55x | 0.55x | 0.65x | 0.67x | 0.43x | 0.46x | 0.44x | 0.44x |
Asset Growth % | 6.3% | 12.95% | 14.29% | 7.54% | 6.38% | 10.49% | 103.9% | 4.27% | 3.29% | 20.77% |
Total Current Liabilities | 67.19M | 106.83M | 90.01M | 112.2M | 103.81M | 94.86M | 225.41M | 173.76M | 158.16M | 164.48M |
Accounts Payable | 16.63M | 31.32M | 25.06M | 24.36M | 22.21M | 20.5M | 25.44M | 30.51M | 32.59M | 35.5M |
Days Payables Outstanding | 40.63 | 60.92 | 48.03 | 43.05 | 34.06 | 29.92 | 31.66 | 31.1 | 32.7 | 36.2 |
Short-Term Debt | 6.31M | 18.23M | 10.92M | 12.26M | 2.2M | 3.05M | 436K | 234K | 1.64M | 11.38M |
Deferred Revenue (Current) | 0 | -56.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7.78M | 0 | 30.12M | 25.19M | 23.16M | 17.55M | 0 | 0 | 0 | 86.61M |
Current Ratio | 2.79x | 2.06x | 2.84x | 2.49x | 3.06x | 3.99x | 2.17x | 3.07x | 4.02x | 3.85x |
Quick Ratio | 1.85x | 1.41x | 1.61x | 1.63x | 2.17x | 2.90x | 1.70x | 2.19x | 2.90x | 2.82x |
Cash Conversion Cycle | 169.5 | 138.51 | 215.14 | 196.96 | 173.95 | 186.2 | 165.46 | 194.43 | 217.55 | 210.65 |
Total Non-Current Liabilities | 50.14M | 42.37M | 69.43M | 70.31M | 122.2M | 118.47M | 648.08M | 671.41M | 682.34M | 710.29M |
Long-Term Debt | 40.84M | 31.98M | 38.89M | 33.91M | 74.38M | 72.84M | 589.58M | 601.63M | 608.66M | 609.8M |
Capital Lease Obligations | 0 | 0 | 16.82M | 17.74M | 25.1M | 23.69M | 29.72M | 41.88M | 37.77M | 181.38M |
Deferred Tax Liabilities | 2.24M | 1.45M | 867K | 5.45M | 7.07M | 7.37M | 6.07M | 6.96M | 5.93M | 6.96M |
Other Non-Current Liabilities | 7.94M | 9.36M | 12.86M | 13.21M | 15.65M | 14.56M | 22.72M | 20.95M | 29.98M | 35.29M |
Total Liabilities | 117.34M | 149.2M | 159.44M | 182.51M | 226.01M | 213.33M | 873.49M | 845.17M | 840.49M | 874.77M |
Total Debt | 47.16M | 50.21M | 66.63M | 67.27M | 104.66M | 102.58M | 623.64M | 650.55M | 656M | 686.38M |
Net Debt | -18.44M | -36.12M | -8.93M | -25.37M | -21.69M | -53.52M | 479.35M | 498.94M | 485.82M | 515.2M |
Debt / Equity | 0.14x | 0.14x | 0.16x | 0.15x | 0.23x | 0.19x | 0.98x | 0.89x | 0.83x | 0.89x |
Debt / EBITDA | 3.16x | 6.36x | 3.16x | 1.86x | 1.09x | 0.76x | 2.61x | 2.48x | 4.40x | 4.57x |
Net Debt / EBITDA | -1.24x | -4.58x | -0.42x | -0.70x | -0.22x | -0.39x | 2.01x | 1.90x | 3.26x | 3.43x |
Interest Coverage | 2.51x | -39.85x | 507.12x | 13.40x | 96.07x | 63.86x | 7.31x | 7.25x | 5.85x | 4.88x |
Total Equity | 337.33M▲ 0% | 364.36M▲ 8.0% | 427.53M▲ 17.3% | 448.72M▲ 5.0% | 445.52M▼ 0.7% | 528.66M▲ 18.7% | 639.42M▲ 21.0% | 732.3M▲ 14.5% | 788.8M▲ 7.7% | 773.39M▲ 0% |
Equity Growth % | 2.45% | 8.01% | 17.34% | 4.96% | -0.71% | 18.66% | 20.95% | 14.53% | 7.72% | 23.59% |
Book Value per Share | 6.97 | 7.85 | 8.57 | 9.13 | 8.95 | 10.08 | 12.06 | 14.07 | 16.36 | 16.65 |
Total Shareholders' Equity | 337.33M | 332.44M | 381.37M | 402.31M | 445.52M | 528.66M | 639.42M | 732.3M | 788.8M | 773.39M |
Common Stock | 5K | 5K | 5K | 5K | 6K | 6K | 6K | 6K | 6K | 6K |
Retained Earnings | 76.23M | 67.48M | 116.37M | 117.77M | 180.34M | 271.72M | 409.27M | 568.79M | 666.88M | 673.3M |
Treasury Stock | -50.7M | -75.48M | -97.63M | -121.81M | -150.48M | -189.52M | -247.43M | -332.71M | -408.15M | -438M |
Accumulated OCI | -2.1M | -4.01M | -4.69M | -3.72M | -6.76M | -8.62M | -8.48M | -9.18M | -5.31M | -5.74M |
Minority Interest | 0 | 31.92M | 46.16M | 46.42M | 0 | 0 | 0 | 0 | 0 | 0 |
AMPH Cash Flow Statement
Amphastar Pharmaceuticals, Inc. (AMPH) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 39.21M | 38.19M | 41.76M | 57.27M | 97.99M | 89.18M | 183.5M | 213.39M | 156.12M | 168.88M |
Operating CF Margin % | 16.33% | 12.96% | 12.96% | 16.37% | 22.38% | 17.87% | 28.48% | 29.15% | 21.69% | - |
Operating CF Growth % | 1.68% | -2.6% | 9.35% | 37.12% | 71.12% | -8.99% | 105.76% | 16.28% | -26.84% | -11.19% |
Net Income | 4.51M | -6.66M | 46.51M | 1.1M | 63.3M | 91.39M | 137.54M | 159.52M | 98.09M | 79.23M |
Depreciation & Amortization | 15.44M | 16.52M | 21.12M | 25.18M | 26.75M | 28.74M | 41.78M | 57.2M | 63.2M | 57.48M |
Stock-Based Compensation | 17.09M | 16.68M | 17.3M | 20.5M | 18.69M | 17.86M | 20.24M | 24.37M | 27.28M | 28.16M |
Deferred Taxes | 3.93M | -1.88M | 7.55M | 1.12M | 4.21M | -15.75M | -13.74M | -17.87M | 27.63M | 0 |
Other Non-Cash Items | -2.34M | 1.43M | 1.04M | 240K | -13.03M | -878K | 21.89M | 4.71M | 5.89M | 37.96M |
Working Capital Changes | 582K | 12.1M | -51.75M | 9.13M | -1.92M | -32.18M | -24.21M | -14.55M | -65.97M | -33.95M |
Change in Receivables | -8.1M | -16.3M | 6.7M | -20.16M | -14.92M | -10.13M | -26.09M | -21.67M | -6.37M | -2.84M |
Change in Inventory | 18.65M | -5.98M | -41.1M | 15.3M | 1.26M | -11.75M | -1.72M | -48.8M | -21.06M | 16.3M |
Change in Payables | 6.69M | 29.16M | -17.94M | 14.96M | 3.02M | -736K | 13.24M | 63.56M | -4.56M | -12.56M |
Cash from Investing | -38.76M | -42.18M | -50.53M | -36.41M | -28.67M | -32.78M | -649.12M | -124.93M | -70.33M | -97.55M |
Capital Expenditures | -35.1M | -46.81M | -41.55M | -33.85M | -27.46M | -24.03M | -38.17M | -41.04M | -34.88M | -33.69M |
CapEx % of Revenue | 14.61% | 15.89% | 12.89% | 9.68% | 6.27% | 4.82% | 5.92% | 5.61% | 4.85% | 4.68% |
Acquisitions | 2M | 4.64M | 0 | 0 | 0 | 421K | -506.41M | -129M | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -3.66M | 198K | -157K | -1.41M | -2.61M | -1.37M | 1.39M | -4.12M | -6.61M | -6.54M |
Cash from Financing | -7.72M | 25.01M | -3.78M | -2.25M | -37.02M | -26.44M | 454.09M | -80.95M | -67.42M | -83.13M |
Debt Issued (Net) | 9.27M | 3.07M | -3.21M | -880K | 32.1M | -1.78M | 526.34M | 10.17M | 5.31M | -1.63M |
Equity Issued (Net) | -30.75M | 12.99M | -3.99M | -24.43M | -28.87M | -39.91M | -58.14M | -85.46M | -72.73M | -37.03M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -30.75M | -25.05M | -22.29M | -24.43M | -28.87M | -39.91M | -58.14M | -85.46M | -75.59M | -39.01M |
Other Financing | 13.76M | 8.95M | 3.42M | 23.06M | -40.24M | 15.25M | -14.11M | -5.67M | 0 | -44.47M |
Net Change in Cash | -6.76M▲ 0% | 20.74M▲ 406.8% | -12.65M▼ 161.0% | 18.96M▲ 249.8% | 32.08M▲ 69.2% | 29.75M▼ 7.3% | -11.8M▼ 139.7% | 7.31M▲ 162.0% | 18.57M▲ 153.9% | -11.84M▲ 0% |
Free Cash Flow | 4.11M▲ 0% | -8.62M▼ 309.7% | 207K▲ 102.4% | 23.41M▲ 11209.7% | 70.54M▲ 201.3% | 65.15M▼ 7.6% | 145.34M▲ 123.1% | 172.34M▲ 18.6% | 121.23M▼ 29.7% | 135.19M▲ 0% |
FCF Margin % | 1.71% | -2.92% | 0.06% | 6.69% | 16.11% | 13.06% | 22.55% | 23.55% | 16.84% | 18.76% |
FCF Growth % | -76.07% | -309.66% | 102.4% | 11209.66% | 201.3% | -7.64% | 123.09% | 18.58% | -29.66% | -10.01% |
FCF per Share | 0.08 | -0.19 | 0.00 | 0.48 | 1.42 | 1.24 | 2.74 | 3.31 | 2.51 | 2.91 |
FCF Conversion (FCF/Net Income) | 8.70x | -6.66x | 0.85x | 40.82x | 1.58x | 0.98x | 1.33x | 1.34x | 1.59x | 1.71x |
Interest Paid | 1.88M | 2.38M | 2.44M | 2.2M | 2.11M | 3.02M | 17.57M | 26.81M | 23.22M | 15.64M |
Taxes Paid | 4.88M | 339K | 5.72M | 3.41M | 8.1M | 44.44M | 49M | 40.1M | 22.71M | 21.81M |
AMPH Key Ratios
Amphastar Pharmaceuticals, Inc. (AMPH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 1.35% | -1.64% | 12.36% | 0.32% | 13.89% | 18.76% | 23.55% | 23.26% | 12.9% | 10.23% |
Return on Invested Capital (ROIC) | -0.22% | -2% | -0.01% | 1.95% | 12.37% | 17.94% | 18.54% | 13.11% | 8.4% | 7% |
Gross Margin | 37.8% | 36.31% | 40.92% | 40.97% | 45.63% | 49.87% | 54.49% | 51.08% | 49.46% | 47.34% |
Net Margin | 1.88% | -1.95% | 15.18% | 0.4% | 14.19% | 18.31% | 21.34% | 21.79% | 13.63% | 11% |
Debt / Equity | 0.14x | 0.14x | 0.16x | 0.15x | 0.23x | 0.19x | 0.98x | 0.89x | 0.83x | 0.89x |
Interest Coverage | 2.51x | -39.85x | 507.12x | 13.40x | 96.07x | 63.86x | 7.31x | 7.25x | 5.85x | 4.88x |
FCF Conversion | 8.70x | -6.66x | 0.85x | 40.82x | 1.58x | 0.98x | 1.33x | 1.34x | 1.59x | 1.71x |
Revenue Growth | -5.87% | 22.69% | 9.4% | 8.53% | 25.13% | 13.98% | 29.14% | 13.59% | -1.65% | -1.06% |
Related:AMPH Dividend History·AMPH Revenue History·AMPH Price History·AMPH P/E History·AMPH Financial Ratios·AMPH Institutional Holders
AMPH SEC Filings & Documents
Amphastar Pharmaceuticals, Inc. (AMPH) SEC filings — annual & quarterly reports (10-K, 10-Q)
AMPH Frequently Asked Questions
Amphastar Pharmaceuticals, Inc. (AMPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Amphastar Pharmaceuticals, Inc. (AMPH) reported $720.5M in revenue for fiscal year 2025. This represents a 253% increase from $204.3M in 2012.
Amphastar Pharmaceuticals, Inc. (AMPH) saw revenue decline by 1.7% over the past year.
Yes, Amphastar Pharmaceuticals, Inc. (AMPH) is profitable, generating $79.2M in net income for fiscal year 2025 (13.6% net margin).
Dividend & Returns
Amphastar Pharmaceuticals, Inc. (AMPH) has a return on equity (ROE) of 12.9%. This is reasonable for most industries.
Amphastar Pharmaceuticals, Inc. (AMPH) generated $135.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.